Clinical trials: Neoadjuvant Radiotherapy
Gastric or Gastroesophageal Junction Adenocarcinoma
Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ
Gastric cancer is the third leading cause of death due to cancer worldwide. Although the consensus on the surgical treatment has resulted in the improvement of curative effect during the past decades, controversies remained for…
- Trial name
- RARE (NCT05941481)
- Testing
- neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Non-Small Cell Lung Cancer
Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC
In this study, patients with EGFR/ALK wild-type, resectable locally advanced NSCLC are expected to receive 1 cycle of chemoimmunotherapy as neoadjuvant therapy, followed by SBRT to the primary lung lesion, and chemoimmunotherapy…
- Trial name
- NCT06718309
- Testing
- Chemotherapy, Immunotherapy, Radical resection of lung cancer
- Where
- China
- Volunteers
- 40 people
- Sponsor
- First People's Hospital of Hangzhou
Rectal Cancer, pMMR (Microsatellite Stable Rectal Cancer)
Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
This is a multicenter, phase III, randomized controlled trial. Eligible patients with pMMR/MSS locally advanced rectal cancer will be randomized in a 1:1 ratio to either the experimental group or the control group using…
- Trial name
- NCT07528209
- Testing
- Pucotenlimab combine with CAPOX, CAPOX
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Patients diagnosed with locally advanced very low rectal cancer were chosen to participate in a comprehensive neoadjuvant therapy (TNT) protocol.
- Trial name
- TRACE-LE (NCT05969847)
- Testing
- split-course hypofraction radiotherapy, CAPOX, Envafolimab
- Where
- China
- Volunteers
- 72 people
- Sponsor
- 池畔
Rectal Cancer Patients
Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC
This study is a single-center, prospective, single-arm, open-label, Phase II clinical trial designed to evaluate the efficacy of radiotherapy combined with CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as neoadjuvant therapy…
- Trial name
- NCT07291401
- Testing
- lparomlimab and Tuvonralimab Injection and CPAOX and radiotherapy
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Zhongnan Hospital
Rectal Cancer
Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria
Why is this study conducted? The purpose of this study is to improve the treatment efficacy, particularly the pathological complete response rate, in patients with high-risk/extremely high-risk locally advanced rectal cancer…
- Trial name
- STARS-RC10 (NCT07505472)
- Testing
- Experimental Group, Control group
- Where
- China
- Volunteers
- 212 people
- Sponsor
- The First Hospital of Jilin University
Rectal Neoplasms
Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer
Locally advanced rectal cancer (T3, T4 or lymph node positive tumors) are conventionally treated with 5FU / capecitabine based chemoradiation prior to surgical resection.
- Trial name
- NCT02137356
- Testing
- standard dose pelvic radiation therapy, standard dose capecitabine, dose-escalated selinexor treatment
- Where
- Israel
- Volunteers
- 28 people
- Sponsor
- Sheba Medical Center
Rectal Carcinoma
Neoadjuvant Treatment for Advanced Rectal Carcinoma
The purpose of the study is to compare pre-operative radio-chemotherapy (RT + capecitabine) to a short course RT associated with a delayed surgery, with two primary objectives: the efficacy evaluation (rate of R0 resection) and…
- Trial name
- NACRE (NCT02551237)
- Testing
- 50 Gy, Capecitabine, 25 Gy
- Where
- 37 sites in France
- Volunteers
- 103 people
- Sponsor
- UNICANCER
Breast Cancer
De-escalation of RNI in Breast Cancer Patients With pN0 After Neoadjuvant Therapy
Prospective Comparative Study of Response-Adapted De-escalation of Regional Nodal Irradiation in Initially Node Positive Breast Cancer Patients with Pathological Nodal Complete Response After Neoadjuvant Therapy
- Trial name
- OMIT-RNI (NCT07724769)
- Testing
- Adjuvant Radiotherapy
- Volunteers
- 100 people
- Sponsor
- Aya Ahmed Sayed
Breast Cancer
Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy
Postoperative radiotherapy is generally recommended for patients with breast cancer who have undergone breast-conserving surgery, regardless of prior chemotherapy.
- Trial name
- NCT05993559
- Testing
- Arm I (No PMRT), Arm II (PMRT)
- Volunteers
- 1,314 people
- Sponsor
- Gangnam Severance Hospital
NSCLC (Non-small Cell Lung Cancer)
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
his multicenter, open-label, single-arm phase I/II trial will evaluate the safety, tolerability, and preliminary efficacy of oral paclitaxel solution combined with an immune checkpoint inhibitor and concurrent stereotactic body…
- Trial name
- NCT07754812
- Testing
- Oral Paclitaxel Solution, PD-1/PD-L1 inhibitor, Stereotactic Body Radiotherapy (SBRT)
- Where
- 5 sites in China
- Volunteers
- 78 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Breast Neoplasms
Internal Mammary Node Irradiation After Neoadjuvant Systemic Therapy for Breast Cancer
This multicenter randomized controlled trial evaluates whether internal mammary node irradiation (IMNI) improves oncologic outcomes in patients with breast cancer who have residual pathologically positive lymph nodes after…
- Trial name
- IMN-Neo (NCT07915739)
- Testing
- Locoregional Radiotherapy With Internal Mammary Node Irradiation, Locoregional Radiotherapy Without Internal Mammary Node Irradiation
- Where
- 9 sites in Thailand
- Volunteers
- 1,760 people
- Sponsor
- Mahidol University
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease.
- Trial name
- NCT02405585
- Testing
- mFOLFIRINOX, Algenpantucel-L Immunotherapy, SBRT
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- NewLink Genetics Corporation
Breast Cancer
Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer
The purpose of this study is to determine whether Cisplatin when given with radiation therapy prior to surgery is effective in improving response to treatment in breast cancer patients.
- Trial name
- NCT00603408
- Testing
- Cisplatin, Radiation Therapy, Mastectomy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy
To de-escalate radiation therapy in women with breast cancer.
- Trial name
- ROSALIE (NCT05866458)
- Where
- 27 sites in Australia, Canada
- Volunteers
- 352 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Prostate Cancer
Preoperative Radiation Therapy for High Risk Prostate Cancer
This is a Phase I dose-escalation study of moderate dose radiation therapy prior to radical prostatectomy for patients with high-risk localized disease.
- Trial name
- NCT01041326
- Testing
- Radiation, Radical Prostatectomy
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Esophageal Squamous Cell Carcinoma (ESCC)
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant toripalimab combined with chemotherapy and low-dose radiotherapy in patients with esophageal squamous cell carcinoma who are insensitive to…
- Trial name
- NCT07272291
- Testing
- Toripalimab
- Volunteers
- 48 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Neoplasm Female, Lymphatic Metastasis
Omitting Biopsy of SEntinel Lymph Node With Radiation After Neoadjuvant Chemotherapy in Breast Cancer (OBSERB) Trial
The OBSERB study is a multi-center, non-blinded, pragmatic, parallel, randomized controlled trial in which patients with cT1-3N1 and ycN0 breast cancer.
- Trial name
- OBSERB (NCT04116125)
- Testing
- Radiotherapy
- Volunteers
- 1,380 people
- Sponsor
- Kyungpook National University Chilgok Hospital
Prostate Cancer
Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. Hormone therapy combined with radiation therapy may be a more effective treatment for prostate cancer.
- Trial name
- NCT00769548
- Testing
- flutamide, goserelin acetate, low-LET photon therapy
- Volunteers
- 1,322 people
- Sponsor
- Radiation Therapy Oncology Group
Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy
Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to investigate the safety and efficacy of HFRT plus neoadjuvant ICT in locally advanced resectable GEJA.
- Trial name
- NCT07182565
- Testing
- hypofractionated radiotherapy, PD-1 inhibitor, TS-1
- Where
- 4 sites in China
- Volunteers
- 84 people
- Sponsor
- West China Hospital